organization · Reporting owner
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MedAvail Holdings, Inc.MDVL · Entity 94590 | 10% owner | June 16, 2023 | June 21, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MedAvail Holdings, Inc.
Report date June 16, 2023 · Filed June 21, 2023
Jointly reported with ABG WTT-MedAvail Ltd, ABG-WTT Global Life Science Capital Partners GP, L.P., ABG-WTT Global Life Science Capital Partners GP Ltd, ABG Management Ltd., Yu Fan, Ally Bridge MedAlpha Master Fund L.P., Ally Bridge Group (NY) LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series A Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.39 · Expires 2028-06-16 | IndirectSee footnote | 6,818,181 |
Reported balance
After 2023-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-16 · Other · Acquired 6,818,181 · Balance 6,818,181 F1: On March 13, 2023, pursuant to the securities purchase agreement, dated as of March 9, 2023 (the "2023 Securities Purchase Agreement"), by and among the Issuer and the certain purchasers listed therein, ABG WTT-MedAvail Limited ("ABG WTT") and Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha") purchased from the Issuer 6,818,181 and 965,130 Pre-Funded Warrants, respectively, at a purchase price of $0.3212 per share. Pursuant to the 2023 Securities Purchase Agreement, ABG WTT and MedAlpha also purchased for no additional consideration 6,818,181 and 965,130 Series A Warrants, respectively. The Series A Warrants were issued two business days following the date the Issuer received required approval of the Issuer's stockholders on June 14, 2023. F2: These securities are held of record by ABG WTT. ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. |
| Series A Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.39 · Expires 2028-06-16 | IndirectSee footnote | 965,130 |
Reported balance
After 2023-06-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-16 · Other · Acquired 965,130 · Balance 965,130 F1: On March 13, 2023, pursuant to the securities purchase agreement, dated as of March 9, 2023 (the "2023 Securities Purchase Agreement"), by and among the Issuer and the certain purchasers listed therein, ABG WTT-MedAvail Limited ("ABG WTT") and Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha") purchased from the Issuer 6,818,181 and 965,130 Pre-Funded Warrants, respectively, at a purchase price of $0.3212 per share. Pursuant to the 2023 Securities Purchase Agreement, ABG WTT and MedAlpha also purchased for no additional consideration 6,818,181 and 965,130 Series A Warrants, respectively. The Series A Warrants were issued two business days following the date the Issuer received required approval of the Issuer's stockholders on June 14, 2023. F3: These securities are held of record by MedAlpha. Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 13, 2023, pursuant to the securities purchase agreement, dated as of March 9, 2023 (the "2023 Securities Purchase Agreement"), by and among the Issuer and the certain purchasers listed therein, ABG WTT-MedAvail Limited ("ABG WTT") and Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha") purchased from the Issuer 6,818,181 and 965,130 Pre-Funded Warrants, respectively, at a purchase price of $0.3212 per share. Pursuant to the 2023 Securities Purchase Agreement, ABG WTT and MedAlpha also purchased for no additional consideration 6,818,181 and 965,130 Series A Warrants, respectively. The Series A Warrants were issued two business days following the date the Issuer received required approval of the Issuer's stockholders on June 14, 2023.
F2: These securities are held of record by ABG WTT. ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership.
F3: These securities are held of record by MedAlpha. Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2023 Filed Jun 21, 2023 16:05 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | OtherSeries A Warrant (Right to Buy) · Derivative | 965,130 | Not disclosed Strike: $0.39 | Not disclosed |
DisclosureSEC source: 0000899243-23-016125 · doc4.xml · derivative · entry 2 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 965,130 Underlying: Common Stock · 965,130 shares Expires 2028-06-16 F1 · kind: On March 13, 2023, pursuant to the securities purchase agreement, dated as of March 9, 2023 (the "2023 Securities Purchase Agreement"), by and among the Issuer and the certain purchasers listed therein, ABG WTT-MedAvail Limited ("ABG WTT") and Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha") purchased from the Issuer 6,818,181 and 965,130 Pre-Funded Warrants, respectively, at a purchase price of $0.3212 per share. Pursuant to the 2023 Securities Purchase Agreement, ABG WTT and MedAlpha also purchased for no additional consideration 6,818,181 and 965,130 Series A Warrants, respectively. The Series A Warrants were issued two business days following the date the Issuer received required approval of the Issuer's stockholders on June 14, 2023. F1 · price: On March 13, 2023, pursuant to the securities purchase agreement, dated as of March 9, 2023 (the "2023 Securities Purchase Agreement"), by and among the Issuer and the certain purchasers listed therein, ABG WTT-MedAvail Limited ("ABG WTT") and Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha") purchased from the Issuer 6,818,181 and 965,130 Pre-Funded Warrants, respectively, at a purchase price of $0.3212 per share. Pursuant to the 2023 Securities Purchase Agreement, ABG WTT and MedAlpha also purchased for no additional consideration 6,818,181 and 965,130 Series A Warrants, respectively. The Series A Warrants were issued two business days following the date the Issuer received required approval of the Issuer's stockholders on June 14, 2023. F3 · ownership.nature: These securities are held of record by MedAlpha. Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 16:05 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | OtherSeries A Warrant (Right to Buy) · Derivative | 6,818,181 | Not disclosed Strike: $0.39 | Not disclosed |
DisclosureSEC source: 0000899243-23-016125 · doc4.xml · derivative · entry 1 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 6,818,181 Underlying: Common Stock · 6,818,181 shares Expires 2028-06-16 F1 · kind: On March 13, 2023, pursuant to the securities purchase agreement, dated as of March 9, 2023 (the "2023 Securities Purchase Agreement"), by and among the Issuer and the certain purchasers listed therein, ABG WTT-MedAvail Limited ("ABG WTT") and Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha") purchased from the Issuer 6,818,181 and 965,130 Pre-Funded Warrants, respectively, at a purchase price of $0.3212 per share. Pursuant to the 2023 Securities Purchase Agreement, ABG WTT and MedAlpha also purchased for no additional consideration 6,818,181 and 965,130 Series A Warrants, respectively. The Series A Warrants were issued two business days following the date the Issuer received required approval of the Issuer's stockholders on June 14, 2023. F1 · price: On March 13, 2023, pursuant to the securities purchase agreement, dated as of March 9, 2023 (the "2023 Securities Purchase Agreement"), by and among the Issuer and the certain purchasers listed therein, ABG WTT-MedAvail Limited ("ABG WTT") and Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha") purchased from the Issuer 6,818,181 and 965,130 Pre-Funded Warrants, respectively, at a purchase price of $0.3212 per share. Pursuant to the 2023 Securities Purchase Agreement, ABG WTT and MedAlpha also purchased for no additional consideration 6,818,181 and 965,130 Series A Warrants, respectively. The Series A Warrants were issued two business days following the date the Issuer received required approval of the Issuer's stockholders on June 14, 2023. F2 · ownership.nature: These securities are held of record by ABG WTT. ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
| March 13, 2023 Filed Mar 15, 2023 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchasePre-Funded Warrant (Right to Buy) · Derivative | 965,130 | $0.32 Strike: $0.00 | $309,999.76 |
DisclosureSEC source: 0000899243-23-008565 · doc4.xml · derivative · entry 2 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 965,130 Underlying: Common Stock · 965,130 shares Expires not disclosed F1 · derivative.exercise_date: Prior to the Issuer receiving certain required approval of the Issuer's stockholders (the "Requisite Stockholder Approval"), the Pre-Funded Warrant holders may only exercise up to the product of (i) the holder's pro rata portion of the Pre-Funded Warrants and (ii) 16,025,925, which is the number of shares equal to 19.99% of the Issuer's Common Stock outstanding on March 9, 2023. F2 · derivative.expiration_date: The Pre-Funded Warrants do not expire. F4 · ownership.nature: These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. Read SEC document |
| March 13, 2023 Filed Mar 15, 2023 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchasePre-Funded Warrant (Right to Buy) · Derivative | 6,818,181 | $0.32 Strike: $0.00 | $2,189,999.74 |
DisclosureSEC source: 0000899243-23-008565 · doc4.xml · derivative · entry 1 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 6,818,181 Underlying: Common Stock · 6,818,181 shares Expires not disclosed F1 · derivative.exercise_date: Prior to the Issuer receiving certain required approval of the Issuer's stockholders (the "Requisite Stockholder Approval"), the Pre-Funded Warrant holders may only exercise up to the product of (i) the holder's pro rata portion of the Pre-Funded Warrants and (ii) 16,025,925, which is the number of shares equal to 19.99% of the Issuer's Common Stock outstanding on March 9, 2023. F2 · derivative.expiration_date: The Pre-Funded Warrants do not expire. F3 · ownership.nature: These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseWarrant (Right to Buy) · Derivative | 1,487,058 | $1.06 Strike: $1.25 | $1,579,999.13 |
DisclosureSEC source: 0000899243-22-014088 · doc4.xml · derivative · entry 4 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,487,058 Underlying: Common Stock · 1,487,058 shares Expires 2027-04-04 F2 · ownership.nature: These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. As a result of an internal reorganization, Ally Bridge MedAlpha Management L.P. and Ally Bridge MedAlpha Management GP, LLC are no longer deemed to share beneficial ownership of the securities reported herein. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseWarrant (Right to Buy) · Derivative | 5,571,764 | $1.06 Strike: $1.25 | $5,919,999.25 |
DisclosureSEC source: 0000899243-22-014088 · doc4.xml · derivative · entry 3 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,571,764 Underlying: Common Stock · 5,571,764 shares Expires 2027-04-04 F1 · ownership.nature: These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 2,974,117 | $1.06 | $3,159,999.31 |
DisclosureSEC source: 0000899243-22-014088 · doc4.xml · nonDerivative · entry 2 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,894,897 F2 · ownership.nature: These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, which manages MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. As a result of an internal reorganization, Ally Bridge MedAlpha Management L.P. and Ally Bridge MedAlpha Management GP, LLC are no longer deemed to share beneficial ownership of the securities reported herein. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 11,143,529 | $1.06 | $11,839,999.56 |
DisclosureSEC source: 0000899243-22-014088 · doc4.xml · nonDerivative · entry 1 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 15,029,480 F1 · ownership.nature: These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 16:31 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 5,727 | $15.00 | $85,881.52 |
DisclosureSEC source: 0000899243-21-000379 · doc4.xml · nonDerivative · entry 2 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,920,780 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.83 to $15.00. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of each of Ally Bridge MedAlpha Management GP, LLC and Ally Bridge Group (NY) LLC. Ally Bridge Group (NY) LLC and Ally Bridge MedAlpha Management L.P., acting through its general partner Ally Bridge MedAlpha Management GP, LLC, manage MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 16:31 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 6,943 | $15.00 | $104,116.53 |
DisclosureSEC source: 0000899243-21-000379 · doc4.xml · nonDerivative · entry 1 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,885,951 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.83 to $15.00. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 29, 2020 Filed Dec 30, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 45 | $14.00 | $630.00 |
DisclosureSEC source: 0000899243-20-035506 · doc4.xml · nonDerivative · entry 4 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,915,053 F3 · ownership.nature: These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of each of Ally Bridge MedAlpha Management GP, LLC and Ally Bridge Group (NY) LLC. Ally Bridge Group (NY) LLC and Ally Bridge MedAlpha Management L.P., acting through its general partner Ally Bridge MedAlpha Management GP, LLC, manage MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 29, 2020 Filed Dec 30, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 55 | $14.00 | $770.00 |
DisclosureSEC source: 0000899243-20-035506 · doc4.xml · nonDerivative · entry 3 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,879,008 F2 · ownership.nature: These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 28, 2020 Filed Dec 30, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 3,213 | $13.98 | $44,906.82 |
DisclosureSEC source: 0000899243-20-035506 · doc4.xml · nonDerivative · entry 2 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,915,008 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.85 to $14.00. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of each of Ally Bridge MedAlpha Management GP, LLC and Ally Bridge Group (NY) LLC. Ally Bridge Group (NY) LLC and Ally Bridge MedAlpha Management L.P., acting through its general partner Ally Bridge MedAlpha Management GP, LLC, manage MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 28, 2020 Filed Dec 30, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 3,894 | $13.98 | $54,424.88 |
DisclosureSEC source: 0000899243-20-035506 · doc4.xml · nonDerivative · entry 1 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,878,953 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.85 to $14.00. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 24, 2020 Filed Dec 28, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 4,019 | $13.99 | $56,233.45 |
DisclosureSEC source: 0000899243-20-035198 · doc4.xml · nonDerivative · entry 6 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,911,795 F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.90 to $14.00. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of each of Ally Bridge MedAlpha Management GP, LLC and Ally Bridge Group (NY) LLC. Ally Bridge Group (NY) LLC and Ally Bridge MedAlpha Management L.P., acting through its general partner Ally Bridge MedAlpha Management GP, LLC, manage MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 24, 2020 Filed Dec 28, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 4,871 | $13.99 | $68,154.54 |
DisclosureSEC source: 0000899243-20-035198 · doc4.xml · nonDerivative · entry 5 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,875,059 F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.90 to $14.00. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 9,810 | $13.99 | $137,207.57 |
DisclosureSEC source: 0000899243-20-035198 · doc4.xml · nonDerivative · entry 4 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,907,776 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.91 to $14.00. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of each of Ally Bridge MedAlpha Management GP, LLC and Ally Bridge Group (NY) LLC. Ally Bridge Group (NY) LLC and Ally Bridge MedAlpha Management L.P., acting through its general partner Ally Bridge MedAlpha Management GP, LLC, manage MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 11,890 | $13.99 | $166,299.49 |
DisclosureSEC source: 0000899243-20-035198 · doc4.xml · nonDerivative · entry 3 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,870,188 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.91 to $14.00. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 22, 2020 Filed Dec 28, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 7,661 | $13.70 | $104,967.96 |
DisclosureSEC source: 0000899243-20-035198 · doc4.xml · nonDerivative · entry 2 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,897,966 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.45 to $13.96. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of each of Ally Bridge MedAlpha Management GP, LLC and Ally Bridge Group (NY) LLC. Ally Bridge Group (NY) LLC and Ally Bridge MedAlpha Management L.P., acting through its general partner Ally Bridge MedAlpha Management GP, LLC, manage MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 22, 2020 Filed Dec 28, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 9,287 | $13.70 | $127,246.76 |
DisclosureSEC source: 0000899243-20-035198 · doc4.xml · nonDerivative · entry 1 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,858,298 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.45 to $13.96. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 7,358 | $13.31 | $97,969.56 |
DisclosureSEC source: 0000899243-20-034836 · doc4.xml · nonDerivative · entry 4 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,890,305 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.00 to $13.69. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of each of Ally Bridge MedAlpha Management GP, LLC and Ally Bridge Group (NY) LLC. Ally Bridge Group (NY) LLC and Ally Bridge MedAlpha Management L.P., acting through its general partner Ally Bridge MedAlpha Management GP, LLC, manage MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 8,919 | $13.31 | $118,753.81 |
DisclosureSEC source: 0000899243-20-034836 · doc4.xml · nonDerivative · entry 3 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,849,011 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.00 to $13.69. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 8,408 | $13.59 | $114,303.40 |
DisclosureSEC source: 0000899243-20-034836 · doc4.xml · nonDerivative · entry 2 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,882,947 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.38 to $13.84. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of each of Ally Bridge MedAlpha Management GP, LLC and Ally Bridge Group (NY) LLC. Ally Bridge Group (NY) LLC and Ally Bridge MedAlpha Management L.P., acting through its general partner Ally Bridge MedAlpha Management GP, LLC, manage MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 10,192 | $13.59 | $138,556.16 |
DisclosureSEC source: 0000899243-20-034836 · doc4.xml · nonDerivative · entry 1 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,840,092 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.38 to $13.84. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 1,029 | $14.00 | $14,406.00 |
DisclosureSEC source: 0000899243-20-034482 · doc4.xml · nonDerivative · entry 6 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,874,539 F3 · ownership.nature: These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of each of Ally Bridge MedAlpha Management GP, LLC and Ally Bridge Group (NY) LLC. Ally Bridge Group (NY) LLC and Ally Bridge MedAlpha Management L.P., acting through its general partner Ally Bridge MedAlpha Management GP, LLC, manage MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 1,248 | $14.00 | $17,472.00 |
DisclosureSEC source: 0000899243-20-034482 · doc4.xml · nonDerivative · entry 5 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,829,900 F2 · ownership.nature: These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 5,731 | $13.12 | $75,191.29 |
DisclosureSEC source: 0000899243-20-034482 · doc4.xml · nonDerivative · entry 4 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,873,510 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.99 to $13.99. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of each of Ally Bridge MedAlpha Management GP, LLC and Ally Bridge Group (NY) LLC. Ally Bridge Group (NY) LLC and Ally Bridge MedAlpha Management L.P., acting through its general partner Ally Bridge MedAlpha Management GP, LLC, manage MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 6,946 | $13.12 | $91,132.21 |
DisclosureSEC source: 0000899243-20-034482 · doc4.xml · nonDerivative · entry 3 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,828,652 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.99 to $13.99. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 12,851 | $13.06 | $167,848.20 |
DisclosureSEC source: 0000899243-20-034482 · doc4.xml · nonDerivative · entry 2 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,867,779 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.00 to $13.20. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of each of Ally Bridge MedAlpha Management GP, LLC and Ally Bridge Group (NY) LLC. Ally Bridge Group (NY) LLC and Ally Bridge MedAlpha Management L.P., acting through its general partner Ally Bridge MedAlpha Management GP, LLC, manage MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 16:30 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 15,578 | $13.06 | $203,465.82 |
DisclosureSEC source: 0000899243-20-034482 · doc4.xml · nonDerivative · entry 1 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,821,706 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.00 to $13.20. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 21:00 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 9,027 | $13.08 | $118,092.12 |
DisclosureSEC source: 0000899243-20-034209 · doc4.xml · nonDerivative · entry 6 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,854,928 F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.00 to $13.38. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of each of Ally Bridge MedAlpha Management GP, LLC and Ally Bridge Group (NY) LLC. Ally Bridge Group (NY) LLC and Ally Bridge MedAlpha Management L.P., acting through its general partner Ally Bridge MedAlpha Management GP, LLC, manage MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 21:00 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 10,942 | $13.08 | $143,144.34 |
DisclosureSEC source: 0000899243-20-034209 · doc4.xml · nonDerivative · entry 5 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,806,128 F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.00 to $13.38. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 21:00 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 4,276 | $12.50 | $53,430.76 |
DisclosureSEC source: 0000899243-20-034209 · doc4.xml · nonDerivative · entry 4 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,845,901 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.29 to $12.995. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of each of Ally Bridge MedAlpha Management GP, LLC and Ally Bridge Group (NY) LLC. Ally Bridge Group (NY) LLC and Ally Bridge MedAlpha Management L.P., acting through its general partner Ally Bridge MedAlpha Management GP, LLC, manage MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 21:00 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 5,184 | $12.50 | $64,776.67 |
DisclosureSEC source: 0000899243-20-034209 · doc4.xml · nonDerivative · entry 3 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,795,186 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.29 to $12.995. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:00 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 6,535 | $12.24 | $80,016.50 |
DisclosureSEC source: 0000899243-20-034209 · doc4.xml · nonDerivative · entry 2 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,841,625 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.0125 to $12.62. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of each of Ally Bridge MedAlpha Management GP, LLC and Ally Bridge Group (NY) LLC. Ally Bridge Group (NY) LLC and Ally Bridge MedAlpha Management L.P., acting through its general partner Ally Bridge MedAlpha Management GP, LLC, manage MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 21:00 UTC | MedAvail Holdings, Inc. MDVL · Entity 94590 | PurchaseCommon Stock | 7,922 | $12.24 | $96,999.34 |
DisclosureSEC source: 0000899243-20-034209 · doc4.xml · nonDerivative · entry 1 ABG WTT-MedAvail Ltd · CIK 0001832110 · 10% owner Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. · CIK 0001808684 · 10% owner ABG-WTT Global Life Science Capital Partners GP, L.P. · CIK 0001832109 · 10% owner ABG-WTT Global Life Science Capital Partners GP Ltd · CIK 0001832108 · 10% owner ABG Management Ltd. · CIK 0001832106 · 10% owner Yu Fan · CIK 0001668029 · 10% owner Ally Bridge MedAlpha Master Fund L.P. · CIK 0001831963 · 10% owner Ally Bridge MedAlpha Management L.P. · CIK 0001766516 · 10% owner Ally Bridge MedAlpha Management GP, LLC · CIK 0001832107 · 10% owner Ally Bridge Group (NY) LLC · CIK 0001822947 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,790,002 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.0125 to $12.62. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.